Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Conditions
This trial is treating people with Non Small Cell Lung Cancer, Melanoma, Renal Cell Cancer, Kidney Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer
Eligibility
Inclusion
Renal Cell Carcinoma Inclusion Criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
- Documented pathologic diagnosis of clear cell RCC.
- Relapsed or refractory to 1-2 prior lines of therapy containing at least an anti-PD-(L)1 agent.
- Measurable disease according to RECIST v1.1
- Mandatory newly collected tumor biopsy sample obtained prior to treatment initiation.
Metastatic Castration-Resistant Prostate Cancer Inclusion Criteria
- Documentation of disease: progressive CRPC with histologically or cytologically confirmed adenocarcinoma of the prostate.
-
Patients must have radiologically evident metastatic disease, but it can be measurable or non-measurable disease:
- Measurable disease: nodal, visceral, or extra nodal lesions according to RECIST v1.1 using a diagnostic computed tomography
- Non-measurable disease: bone only disease (up to 1/3 of study population) per PCWG3 criteria
- 1-3 prior lines of therapy, including at least one newer generation androgen synthesis inhibitor (e.g., abiraterone) or androgen receptor antagonist (e.g., enzalutamide, apalutamide, darolutamide).
- Mandatory newly collected tumor biopsy sample obtained prior to treatment initiation.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
Exclusion
Renal Cell Carcinoma Exclusion Criteria
- History of severe hypersensitivity reaction to monoclonal antibodies.
- Has immunodeficiency or requires treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressant medication during study treatment.
- Has an active autoimmune disease requiring systemic treatment with in the past 2 years OR a documented history of clinically severe autoimmune disease.
Metastatic Castration-Resistant Prostate Cancer Exclusion Criteria
- Has pure small-cell histology and variants with predominant (≥ 50%) neuroendocrine differentiation.
- Has a history of severe hypersensitivity reaction to monoclonal antibodies.
- Has immunodeficiency or requires treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressant medication during study treatment.
- Has an active autoimmune disease requiring systemic treatment with in the past 2 years OR a documented history of clinically severe autoimmune disease.
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
- You are currently being treated on a clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Corvus Pharmaceuticals, Inc
Scientific Title
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information